Becton, Dickinson and Company (BDX) Holdings Reduced by Jarislowsky Fraser Ltd

Jarislowsky Fraser Ltd cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 852,155 shares of the medical instruments supplier’s stock after selling 6,151 shares during the quarter. Becton, Dickinson and comprises approximately 1.0% of Jarislowsky Fraser Ltd’s investment portfolio, making the stock its 24th biggest position. Jarislowsky Fraser Ltd owned 0.37% of Becton, Dickinson and worth $166,979,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of BDX. MAI Capital Management acquired a new position in Becton, Dickinson and in the first quarter valued at $218,000. BB&T Securities LLC lifted its holdings in shares of Becton, Dickinson and by 2.0% in the first quarter. BB&T Securities LLC now owns 96,311 shares of the medical instruments supplier’s stock valued at $17,667,000 after purchasing an additional 1,846 shares in the last quarter. ZWJ Investment Counsel Inc. raised its holdings in shares of Becton, Dickinson and by 204.5% during the first quarter. ZWJ Investment Counsel Inc. now owns 5,252 shares of the medical instruments supplier’s stock worth $963,000 after acquiring an additional 3,527 shares in the last quarter. Credit Agricole S A grew its position in shares of Becton, Dickinson and by 2.9% in the first quarter. Credit Agricole S A now owns 452,439 shares of the medical instruments supplier’s stock valued at $82,996,000 after purchasing an additional 12,892 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Becton, Dickinson and in the first quarter valued at about $2,201,000. 86.01% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down $0.75 during mid-day trading on Wednesday, reaching $219.71. 108,877 shares of the company’s stock traded hands, compared to its average volume of 1,332,307. Becton, Dickinson and Company has a twelve month low of $161.29 and a twelve month high of $225.23. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. The company has a market capitalization of $50,064.30, a price-to-earnings ratio of 23.18, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the previous year, the company earned $2.12 EPS. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

A number of research analysts have recently issued reports on BDX shares. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $230.00 target price (up from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Tuesday, October 31st. Finally, Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $213.47.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the completion of the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The disclosure for this sale can be found here. In the last three months, insiders sold 47,038 shares of company stock valued at $9,480,225. Corporate insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/15/becton-dickinson-and-company-bdx-holdings-reduced-by-jarislowsky-fraser-ltd.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply